Zacks Investment Research on MSN2d
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...
Fierce Pharma16h
A closer look at pharma’s top patent losses in 2025
Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...
Chosunbiz2d
Osteoporosis drug Prolia faces intense competition as patents expire and generics launch
Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the ...
Zacks Investment Research on MSN3d
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...
Behind the Scenes of Amgen's Latest Options Trends
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Chosunbiz3d
Samsung Biologics, Hanmi Pharmaceutical Partner to Sell Prolia Biosimilar in Korea
Samsung Biologics, Hanmi Pharmaceutical Partner to Sell Prolia Biosimilar in Korea Samsung Bioepis and Hanmi Pharmaceutical ...
Amgen outlook revised to positive by Fitch, ratings affirmed
Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...
Yahoo Finance3d
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
Amgen’s stock has been rising consistently ... Sales of best-selling drugs, Prolia and Xgeva, are expected to decline in 2025 due to biosimilar competition. Let’s understand these factors ...